Lumibird SA · EURONEXT:LBIRD

Lumibird SA — H1 2022 Earnings Presentation

26 slides from Lumibird SA's earnings presentation, Sep 23, 2022

  1. Slide 1: H1 2022 results

    fa ~ a 2 ~) —l | H1 2022 results a (v4 w a < 4 Zz < x Bb w in =

  2. Slide 2: Speakers

    Speakers Marc LE FLOHIC Jean-Marc GENDRE Sai d RUTNAM President Deputy Managing Director Transforrmat GittEY CT

  3. Slide 3: Agenda

    1 Strategic direction maintained 2 H1 2022 activity: continued steady growth 3 H1 2022 results: investing in the future 4, Outlook

  4. Slide 4: Strategic direction maintained

    Zz Oo j— U Lu a AQ Y UO Lud — <— or — Y)

  5. Slide 5: A European leader in lasers with a worldwide presence

    A European leader in lasers with a worldwide presence Presence in A fast growing tech company (Revenues in M€ 126.7 g51 100.7. NOT » PEL production sites = 2016 2017 2018 2019 2020 2021 €162.5m Photonics MW Lasers and laser systems for industrial of 2021 turnover Revenues 2021 integrators, R&D centr

  6. Slide 6: Lidar

    Lidar Market trends a 8 op val ~€0.2bn al ~€0.8bn 2019 2019 Study source: Source: Laser world four com, expert interviews, desk research LUMIBIRD positioning Supplier of laser technologies to Lidar manufacturers and supplier of Lidar to Lidar integrators (from component to system) Clients / Targets

  7. Slide 7: Defence / Space

    Defence / Space Market trends Cr Study source: Strategies Unlimited LUMIBIRD positioning LUMIBIRD's offer on the 3 main laser technologies: solid state, fibre, diodes - with lasers, amplifiers and lidar systems Clients / Targets : * THALES, SAFRAN, MBDA, ARIANE, ESA, LEONARDO, US integrators Structu

  8. Slide 8: Ophthalmology market segments

    RETINA GLAUCOMA CATARACT • • 11 B$ 6.1B$ 8B$ CAGR CAGR CAGR 8.1% 3.2% 4.5% • DRY EYE • 4.9 B$ • CAGR 6.1% • 8

  9. Slide 9: H1 2022 activity: continued steady growth

  10. Slide 10: H1 2022 sales at €84m (+11%)

    H1 2022 sales at €84m (+11%) €84.0m €75.5m Defence/Space Industrial & Scientific T +11% “7am 34.7 Photonics Lidar sensors €11.0m CES F +11% $1 2021 S51 2022 MEE Photonics MEE Medical * Growth at +11% in line with 2021 - +9% at constant scope and exchange rates * Scientific/industrial (+2%) - Medical

  11. Slide 11: Highlights of the half-year

    Highlights of the half-year " Protecting the future: Investments in H1 2022 to structure and support growth in H2 2022 and in the years to come. Continued strong demand Strong order book for H2 and 2023 Continued strategic investments Increase in stocks to serve H2 and 2023 component supply context

  12. Slide 12: Finalization of the Saab deal

    Finalization of the Saab deal Acquisition of the Saab Group's Defence Laser . . . . Renee cndenbusiness Rapid synergies and integration + 10m turnover 2021 (standalone) Integration into a new subsidiary: + 33 employees Lumibird Photonics Sweden + Designation rangefinders for air, land and sea Extens

  13. Slide 13: H1 2022 results: investing in the future

  14. Slide 14: Key figures June 2022

    Key figures June 2022 2021-June 2022-June Change Turnover 75.4 84.0 +8.6 +11% Gross margin 47.6 52.4 +4.8 +10% %o. 63.1% 62.4% EBITDA” 14.3 11.2 G.1) 22% % 19.0% 13.3% Current operating income 8.6 3.9 (4.7) 55% %. 11.4% 4.6% _Operating income ‘Tax (1.8) (0.9) 0.9 Net income 5.1 12 (3.8) % 6.7% 1.5%

  15. Slide 15: Evolution of the operating profit by nature

    Evolution of the operating profit by nature (€m) 4,8 =2,7 8,6 ~5,2 mz 3.9 =1,0 = -0,6 Evolution exten Evolution of opens ; olution 0 iat ‘ - 2021-H1 lise expenses seroma Depreciation Capone anil Current nt costs amortization ti operating operating income income

  16. Slide 16: Focus on the evolution of expenses

    Focus on the evolution of expenses Increase in external costs: + €2.7m Travel expenses: €1.3m Resumption of post-Covid travel Return of these expenses to a lower level Finalisation of the ELLEX integration than before COVID in the 2019 Proforma '_e Marketing: + €0.7m , Resumption of post-Covid-19 tr

  17. Slide 17: A structuring effort in the two divisions

    A structuring effort in the two divisions Photonics Medical 2021-H1 2022-H1 nge (%) | 2021 -H1 2022-H2 Turnover 34.7 38.7 +11.3% 40.7 45-4 +11.5% Gross margin 23.2 24.7 +6.4% 24.4 27.7 +13.6% % 66.9% 64.0% 60.0% 61.1% EBITDA” 6.7 3.7 -43.8% 7.6 75 -2.4% % 19.2% 9.7% 18.8% 16.4% Current operating inc

  18. Slide 18: From ROC to net income (Pdg)

    From ROC to net income (Pdg) (€m) 2021-H1 2022-H1 Current operating income 8.6 3.8 Operating income 8.0 2.5 Financial result (1.1) (0.4) Taxes (1.8) (0.9) Net income 5.1 1.2 RO 2022 - impact of non-recurring items: - €1.4m Of which "Scope effect" cost: - €1.3m Financial result : Evolution of the fin

  19. Slide 19: Balance sheet as at June 2022

    Balance sheet as at 30 June 2022 ASSETS LIABILITIES (€m) 31/12/2021 30/06/2022 (€m) 31/12/2021 30/06/2022 Non-current assets 164.8 175.5 Equity 181.3 185.0 Goodwill 70.3 7d Intangibleassets 473 52.2 Non-current liabilities 108.4 105.8 Tangible assets 28.2 32.9 Non-current financial liabilities 97-9

  20. Slide 20: Cash flow generation dedicated to securing the future

    Cash flow generation dedicated to securing the future In me 2021-S1 2022-S1 Of which var. receivables/payables op 38 Of which var. stocks ~ 11.2 Cash flow (before financial expenses and taxes) 14.5 1.0 | of which orher vl 5.1 A receivables/payabies Change in WCR GD ___Gea) Taxes disbursed 1.3 (1.0)

  21. Slide 21: A financial situation adapted to the growth strategy

    A financial situation adapted to the growth strategy Evolution of the net financial debt : 49,2 | 355 20; 7,2 10,6 _0,4 L| 10,6 U 14,9 L ! othernon- 1 cash items: (entryinto the 1 scope of i consolidation / . {rental DEN 2021 Fowor ‘instil Frandelcapex Disbursement seher agreement) DFN 2022-06 ° ope

  22. Slide 22: Outlook

  23. Slide 23: Outlook 2022

    Outlook 2022 Acceleration of growth in H2 Absorption of part of the order book Strong volume effect with accelerated growth Continued gradual price increases Production CSR

  24. Slide 24: Confirmation of 2023 targets

    Confirmation of 2023 targets Doubling of turnover €250m [—* Organic growth: 8 to 10% per year TURNOVER 2023 '—e External growth: targeted on the growth markets of Lidar, Defence and Medical Increase | Profitability _ 20 to 25% EBITDA '—e Integration, synergies, industrialisation, verticalisation Rec

  25. Slide 25: raw

    a as; c o a. raw zt

  26. Slide 26: Distribution of capital

    Distribution of capital Public Esira/Eurodyne 48,07 % 51,93 % 26

Lumibird — H1 2022 Earnings Presentation on 6ix